Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ia bukan cadangan pelaburan.
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Show more...
FAQ
Apakah simbol saham Acticor Biotech?▼
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Stuttgart, saham Acticor Biotech didagangkan di bawah simbol 7V7.STU.
Berapa ramai pekerja yang dimiliki oleh Acticor Biotech?▼
Sehingga September 05, 2026, syarikat mempunyai 31 pekerja.
Acticor Biotech terletak dalam sektor apa?▼
Acticor Biotech beroperasi dalam sektor Kesihatan & Kesejahteraan.
Bilakah Acticor Biotech menyiapkan split saham?▼
Acticor Biotech tidak mempunyai sebarang split baru-baru ini.
Di manakah ibu pejabat Acticor Biotech?▼
Ibu pejabat Acticor Biotech terletak di Paris, Perancis.